PNOC Study in Childhood Brain Cancer Enrols First Patient
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled...
Statement by WuXi AppTec Regarding Recent Market Fluctuation
SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations. View original content:https://www.prnewswire.com/news-releases/statement-by-wuxi-apptec-regarding-recent-market-fluctuation-301445967.html
CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world’s largest organizations dedicated to diagnostics and laboratory informatics
· Combined group to enable better public health outcomes through innovation in diagnostics and laboratory informatics technology TUCSON, Arizona, Jan. 18, 2022 /PRNewswire/ -- CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys. This acquisition and Sunquest combination creates one of the world's largest organizations dedicated to diagnostic...
Ready to Enter the Middle East Market, Vazyme Showcases Its COVID-19 Testing Solutions at Medlab Middle East 2022
DUBAI, UAE, Jan. 28, 2022 /PRNewswire/ -- Leading China-based biotech company Vazyme (688105.SH) participated in the 2022 edition of Medlab Middle East in the Dubai World Trade Centre (DWTC) from January 24th to 27th, a leading laboratory and flagship exhibition and conference that brings together global medical communities to display the best laboratory innovation and technology. At Booth No....
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all HNVs in the Phase I clinical study of its novel...
Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma
Highlights Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2 Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned...
Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers
SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that ATG-022, a Claudin 18.2 antibody drug conjugate (ADC) in-house discovered and developed by Antengene,...
Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China
SUZHOU, China and ROCKVILLE, Md., July 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved a registrational...
Viva Biotech’s Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Tooth Disease Type 1A (CMT1A) patients Acquisition also includes additional early-stage programs in neuromuscular and CNS indications Novartis will make an upfront payment of $500M and additional payments of up to $500M upon...
Centre for Ion Beam Applications at NUS designated as IAEA’s first Collaborating Centre in Singapore
The new collaboration aims to advance accelerator science technologies for multidisciplinary real-world applications SINGAPORE, Sept. 20, 2023 /PRNewswire/ -- The Centre for Ion Beam Applications (CIBA), a multidisciplinary research centre at the National University of Singapore (NUS), has recently been designated as an International Atomic Energy Agency (IAEA) Collaborating Centre for Research and Development...
